Previous close | 29.03 |
Open | 29.10 |
Bid | 29.36 x 300 |
Ask | 29.46 x 200 |
Day's range | 29.03 - 29.90 |
52-week range | 19.80 - 35.50 |
Volume | |
Avg. volume | 740,366 |
Market cap | 1.654B |
Beta (5Y monthly) | 0.86 |
PE ratio (TTM) | N/A |
EPS (TTM) | -6.33 |
Earnings date | 02 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 42.80 |
CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, May 2, 2024, at 8:00 a.m. ET to report its first quarter 2024 financial results and other business highlights. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the co
Agios Pharmaceuticals Inc (NASDAQ:AGIO), a biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of cancer and rare genetic diseases, has seen a recent insider transaction according to the latest SEC filings.
– Report Highlights Company’s Focus on Red Blood Cell Health; Diversity, Equity & Inclusion; and Strong Corporate Governance – – Aligns with the Sustainability Accounting Standards Board (SASB) Standards for the Biotechnology and Pharmaceuticals Industry and the United Nations Sustainable Development Goals (UN SDGs) – CAMBRIDGE, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare dis